Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 20, Issue 12, Pages 2844-2850Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1200/JCO.2002.12.032
Keywords
-
Categories
Funding
- NCI NIH HHS [CA 9154901, CA 16056] Funding Source: Medline
Ask authors/readers for more resources
Purpose : To identify a dose and schedule of oxaliplatin (OXP) to be safely administered in combination with protracted-infusion (PI) fluorouracil (5-FU) and external-beam radiation therapy (XRT) for patients with primary esophageal carcinoma (EC). Patients and Methods: Eligibility included therapeutically naive EC patients with clinical disease stages 11, III, or IV. Initial doses and schedules for cycle I consisted of OXP 85 mg/m(2) on days 1, 15, and 29, PI 5-FU 180 mg/m(2) for 24 hours for 35 days; and XRT 1.8 Gy in 28 fractions starting on day 8. At completion of cycle 1, eligible patients could undergo an operation or begin cycle 2 without XRT. Postoperative patients were eligible for cycle 2. Stage IV patients were allowed three cycles in the absence of disease progression. OXP and 5-FU increases were based on dose-limiting toxicity (DLT) encountered in cohorts of three consecutive patients. Results: Thirty-eight eligible patients received therapy: 22 noninvasively staged as IV and 16 noninvasively staged as 11 and Ill. Thirty-six patients completed cycle 1, 29 patients started cycle 2, and 24 patients completed cycle 2. The combined-modality therapy was well tolerated, but DLT prevented OXP and 5-FU escalation. No grade 4 hematologic toxicity was noted. Eleven grade 3 and two grade 4 clinical toxicities were noted in eight patients. After cycle 1, 29 patients (81%) had no cancer in the esophageal mucosa. Thirteen patients underwent an operation with intent to resect the esophagus; five patients (38%) exhibited pothologic complete responses. Conclusion: OXP 85 mg/m(2) on days 1, 15, and 29 administered with PI 5-FU and XRT is safe, tolerable, and seems effective against primary EC. The role of OXP in multimodality regimens against EC deserves further evaluation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available